LENZ Therapeutics (LENZ) Competitors $41.98 +2.06 (+5.16%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$41.94 -0.04 (-0.11%) As of 09/5/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ vs. ACAD, KRYS, CYTK, MENS, ADMA, PCVX, AAPG, PTCT, ACLX, and AKROShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include ACADIA Pharmaceuticals (ACAD), Krystal Biotech (KRYS), Cytokinetics (CYTK), Jyong Biotech (MENS), ADMA Biologics (ADMA), Vaxcyte (PCVX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), Arcellx (ACLX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. LENZ Therapeutics vs. Its Competitors ACADIA Pharmaceuticals Krystal Biotech Cytokinetics Jyong Biotech ADMA Biologics Vaxcyte Ascentage Pharma Group International PTC Therapeutics Arcellx Akero Therapeutics LENZ Therapeutics (NASDAQ:LENZ) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Is LENZ or ACAD more profitable? ACADIA Pharmaceuticals has a net margin of 21.80% compared to LENZ Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 14.69% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -25.63% -24.43% ACADIA Pharmaceuticals 21.80%14.69%9.41% Do institutionals & insiders hold more shares of LENZ or ACAD? 54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 6.9% of LENZ Therapeutics shares are held by insiders. Comparatively, 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor LENZ or ACAD? In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than LENZ Therapeutics. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 5 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.62 beat ACADIA Pharmaceuticals' score of 0.55 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ACADIA Pharmaceuticals 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LENZ or ACAD? LENZ Therapeutics currently has a consensus price target of $49.60, suggesting a potential upside of 18.15%. ACADIA Pharmaceuticals has a consensus price target of $28.88, suggesting a potential upside of 14.31%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than ACADIA Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00ACADIA Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.61 Which has higher earnings & valuation, LENZ or ACAD? ACADIA Pharmaceuticals has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$49.77M-$1.90-22.09ACADIA Pharmaceuticals$957.80M4.45$226.45M$1.3318.99 Which has more risk and volatility, LENZ or ACAD? LENZ Therapeutics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. SummaryACADIA Pharmaceuticals beats LENZ Therapeutics on 13 of the 16 factors compared between the two stocks. Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$3.13B$5.80B$9.91BDividend YieldN/A2.28%6.71%4.52%P/E Ratio-22.0920.9775.7426.11Price / SalesN/A290.81479.0187.70Price / CashN/A44.9736.9659.04Price / Book5.669.8711.456.09Net Income-$49.77M-$53.42M$3.29B$266.42M7 Day Performance8.67%2.93%1.01%0.45%1 Month Performance39.14%9.85%7.89%4.57%1 Year Performance76.39%15.74%62.80%26.11% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics1.704 of 5 stars$41.98+5.2%$49.60+18.2%+75.8%$1.14BN/A-22.09110Positive NewsACADACADIA Pharmaceuticals3.9581 of 5 stars$25.99-0.9%$28.88+11.1%+55.7%$4.38B$957.80M19.54510Analyst DowngradeKRYSKrystal Biotech4.8938 of 5 stars$147.70-2.0%$210.38+42.4%-19.2%$4.27B$290.52M30.02210Positive NewsCYTKCytokinetics4.0185 of 5 stars$35.33-5.4%$71.58+102.6%-5.2%$4.23B$18.47M-6.93250Trending NewsAnalyst ForecastInsider TradeOptions VolumeMENSJyong BiotechN/A$54.81-1.3%N/AN/A$4.17BN/A0.0031News CoverageGap DownADMAADMA Biologics3.7607 of 5 stars$17.26-0.7%$27.67+60.3%+0.8%$4.12B$426.45M20.07530Positive NewsPCVXVaxcyte2.7193 of 5 stars$30.79+0.1%$136.50+343.3%-70.5%$4.00BN/A-7.49160News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$42.47+3.3%N/AN/A$3.95B$134.35M0.00600Positive NewsGap UpPTCTPTC Therapeutics4.0692 of 5 stars$49.33-0.9%$69.15+40.2%+81.2%$3.92B$806.78M7.081,410News CoverageAnalyst ForecastACLXArcellx2.6379 of 5 stars$69.39-1.2%$114.31+64.7%+3.2%$3.85B$107.94M-20.2980News CoveragePositive NewsAKROAkero Therapeutics4.0077 of 5 stars$46.73-0.4%$81.57+74.6%+69.7%$3.74BN/A-23.3730Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies ACAD Competitors KRYS Competitors CYTK Competitors MENS Competitors ADMA Competitors PCVX Competitors AAPG Competitors PTCT Competitors ACLX Competitors AKRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENZ) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENZ Stock Alerts